{
    "xml": "<topic id=\"PHP2226\" outputclass=\"drug\" rev=\"1.25\" type=\"drug\" namespace=\"/drugs/haloperidol\" basename=\"haloperidol\" title=\"HALOPERIDOL\">\n<title>HALOPERIDOL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_387\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/butyrophenones/haloperidol\">Haloperidol</xref>\n</p>\n<data name=\"vtmid\">10756001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP42329\" outputclass=\"indicationsAndDose\" rev=\"1.67\" parent=\"/drugs/haloperidol\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting in palliative care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1.5&#8239;mg 1&#8211;2 times a day, increased if necessary to 5&#8211;10&#8239;mg daily in divided doses.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By continuous subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8211;15&#8239;mg, to be administered over 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;mg.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8211;10&#8239;mg/24 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia</p>\n<p outputclass=\"therapeuticIndication\">Psychoses</p>\n<p outputclass=\"therapeuticIndication\">Mania and hypomania</p>\n<p outputclass=\"therapeuticIndication\">Organic brain damage (depending on symptoms)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8211;20&#8239;mg once daily, alternatively initially 2&#8211;20&#8239;mg daily in divided doses; maintenance 1&#8211;3&#8239;mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 1&#8211;10&#8239;mg once daily, alternatively initially 1&#8211;10&#8239;mg daily in divided doses; maintenance 1&#8211;3&#8239;mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20&#8239;mg per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8211;5&#8239;mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 1&#8211;2.5&#8239;mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Agitation and restlessness in the elderly</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 0.75&#8211;1.5&#8239;mg 2&#8211;3 times a day, adjusted according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms)</p>\n<p outputclass=\"therapeuticIndication\">Gilles de la Tourette syndrome</p>\n<p outputclass=\"therapeuticIndication\">Severe tics</p>\n<p outputclass=\"therapeuticIndication\">Intractable hiccup</p>\n<p outputclass=\"therapeuticIndication\">Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1.5&#8211;3&#8239;mg 2&#8211;3 times a day, alternatively initially 3&#8211;5&#8239;mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1&#8239;mg 3 times a day, increased if necessary to 2&#8211;3&#8239;mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 0.75&#8211;1.5&#8239;mg 2&#8211;3 times a day, alternatively initially 1.5&#8211;2.5&#8239;mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1&#8239;mg 3 times a day, increased if necessary to 2&#8211;3&#8239;mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Restlessness and confusion in palliative care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8239;mg, then 2&#8239;mg every 2&#8239;hours if required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg, then 2.5&#8239;mg every 2&#8239;hours if required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8211;15&#8239;mg standard 24&#8239;hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41824\" outputclass=\"unlicensedUse\" rev=\"1.18\" parent=\"/drugs/haloperidol\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>BNF doses for schizophrenia, psychoses, mania, hypomania, and organic brain damage differ from those in product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42481\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/haloperidol\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>When prescribing, dispensing or administering, check that this injection is the correct preparation&#8212;this preparation is usually used in hospital for the rapid control of an <i>acute episode</i> and should <b>not</b> be confused with depot preparations which are usually used in the community or clinics for <i>maintenance</i> treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42498\" outputclass=\"contraindications\" rev=\"1.16\" parent=\"/drugs/haloperidol\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Bradycardia</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">lesions of the basal ganglia</ph>; <ph outputclass=\"contraindication\">Parkinson's disease</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">QT-interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42545\" outputclass=\"cautions\" rev=\"1.11\" parent=\"/drugs/haloperidol\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Arteriosclerosis</ph>; <ph outputclass=\"caution\">hypocalcaemia</ph>; <ph outputclass=\"caution\">hypokalaemia</ph>; <ph outputclass=\"caution\">hypomagnesaemia</ph>; <ph outputclass=\"caution\">metabolic disturbances</ph>; <ph outputclass=\"caution\">subarachnoid haemorrhage</ph>; <ph outputclass=\"caution\">thyrotoxicosis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42267\" outputclass=\"interactions\" rev=\"1.14\" parent=\"/drugs/haloperidol\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Avoid concomitant administration of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41978\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/haloperidol\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Depression</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dyspnoea</ph>; <ph outputclass=\"sideEffect\">oedema</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bronchospasm</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia</ph>; <ph outputclass=\"sideEffect\">inappropriate antidiuretic hormone secretion</ph>; <ph outputclass=\"sideEffect\">photosensitivity reactions</ph>; <ph outputclass=\"sideEffect\">pigmentation</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypertension</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Less sedating and fewer antimuscarinic or hypotensive symptoms.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42216\" outputclass=\"pregnancy\" parent=\"/drugs/haloperidol\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless benefits outweigh risks.</p>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42561\" outputclass=\"breastFeeding\" parent=\"/drugs/haloperidol\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42411\" outputclass=\"hepaticImpairment\" parent=\"/drugs/haloperidol\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42107\" outputclass=\"renalImpairment\" parent=\"/drugs/haloperidol\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41773\" outputclass=\"monitoringRequirements\" parent=\"/drugs/haloperidol\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Baseline ECG required before treatment&#8212;assess need for further ECGs during treatment on an individual basis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2226-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/haloperidol\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74919\" title=\"Tablet\" namespace=\"/drugs/haloperidol/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74925\" title=\"Capsule\" namespace=\"/drugs/haloperidol/capsule\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74951\" title=\"Oral solution\" namespace=\"/drugs/haloperidol/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74933\" title=\"Solution for injection\" namespace=\"/drugs/haloperidol/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"5\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"5\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"3\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"2\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_387\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/butyrophenones/haloperidol\" title=\"Haloperidol\" count=\"1\" rel=\"link\">Haloperidol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74919\" namespace=\"/drugs/haloperidol/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74925\" namespace=\"/drugs/haloperidol/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74951\" namespace=\"/drugs/haloperidol/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74933\" namespace=\"/drugs/haloperidol/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2226",
    "outputclass": "drug",
    "rev": "1.25",
    "type": "drug",
    "namespace": "/drugs/haloperidol",
    "basename": "haloperidol",
    "title": "HALOPERIDOL",
    "interactants": [
        {
            "id": "bnf_int_387",
            "label": "Haloperidol"
        }
    ],
    "vtmid": "10756001",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting in palliative care",
                        "html": "Nausea and vomiting in palliative care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion"
                    ],
                    "textContent": "By subcutaneous infusion",
                    "html": "By subcutaneous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 1.5 mg 1&#8211;2 times a day, increased if necessary to 5&#8211;10 mg daily in divided doses.",
                        "html": "<p>Initially 1.5&#8239;mg 1&#8211;2 times a day, increased if necessary to 5&#8211;10&#8239;mg daily in divided doses.</p>"
                    },
                    {
                        "textContent": "5&#8211;15 mg, to be administered over 24 hours.",
                        "html": "<p>5&#8211;15&#8239;mg, to be administered over 24 hours.</p>"
                    },
                    {
                        "textContent": "1&#8211;2 mg.",
                        "html": "<p>1&#8211;2&#8239;mg.</p>"
                    },
                    {
                        "textContent": "2.5&#8211;10 mg/24 hours.",
                        "html": "<p>2.5&#8211;10&#8239;mg/24 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia",
                        "html": "Schizophrenia"
                    },
                    {
                        "textContent": "Psychoses",
                        "html": "Psychoses"
                    },
                    {
                        "textContent": "Mania and hypomania",
                        "html": "Mania and hypomania"
                    },
                    {
                        "textContent": "Organic brain damage (depending on symptoms)",
                        "html": "Organic brain damage (depending on symptoms)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 2&#8211;20 mg once daily, alternatively initially 2&#8211;20 mg daily in divided doses; maintenance 1&#8211;3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20 mg per day.",
                        "html": "<p>Initially 2&#8211;20&#8239;mg once daily, alternatively initially 2&#8211;20&#8239;mg daily in divided doses; maintenance 1&#8211;3&#8239;mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 1&#8211;10 mg once daily, alternatively initially 1&#8211;10 mg daily in divided doses; maintenance 1&#8211;3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20 mg per day.",
                        "html": "<p>Initially 1&#8211;10&#8239;mg once daily, alternatively initially 1&#8211;10&#8239;mg daily in divided doses; maintenance 1&#8211;3&#8239;mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    },
                    {
                        "textContent": "Initially 2&#8211;5 mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12 mg per day.",
                        "html": "<p>Initially 2&#8211;5&#8239;mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 1&#8211;2.5 mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12 mg per day.",
                        "html": "<p>Initially 1&#8211;2.5&#8239;mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Agitation and restlessness in the elderly",
                        "html": "Agitation and restlessness in the elderly"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 0.75&#8211;1.5 mg 2&#8211;3 times a day, adjusted according to response.",
                        "html": "<p>Initially 0.75&#8211;1.5&#8239;mg 2&#8211;3 times a day, adjusted according to response.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms)",
                        "html": "Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms)"
                    },
                    {
                        "textContent": "Gilles de la Tourette syndrome",
                        "html": "Gilles de la Tourette syndrome"
                    },
                    {
                        "textContent": "Severe tics",
                        "html": "Severe tics"
                    },
                    {
                        "textContent": "Intractable hiccup",
                        "html": "Intractable hiccup"
                    },
                    {
                        "textContent": "Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour",
                        "html": "Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 1.5&#8211;3 mg 2&#8211;3 times a day, alternatively initially 3&#8211;5 mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1 mg 3 times a day, increased if necessary to 2&#8211;3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose.",
                        "html": "<p>Initially 1.5&#8211;3&#8239;mg 2&#8211;3 times a day, alternatively initially 3&#8211;5&#8239;mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1&#8239;mg 3 times a day, increased if necessary to 2&#8211;3&#8239;mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose.</p>"
                    },
                    {
                        "textContent": "Initially 0.75&#8211;1.5 mg 2&#8211;3 times a day, alternatively initially 1.5&#8211;2.5 mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1 mg 3 times a day, increased if necessary to 2&#8211;3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose.",
                        "html": "<p>Initially 0.75&#8211;1.5&#8239;mg 2&#8211;3 times a day, alternatively initially 1.5&#8211;2.5&#8239;mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1&#8239;mg 3 times a day, increased if necessary to 2&#8211;3&#8239;mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Restlessness and confusion in palliative care",
                        "html": "Restlessness and confusion in palliative care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion"
                    ],
                    "textContent": "By subcutaneous infusion",
                    "html": "By subcutaneous infusion"
                },
                "adult": [
                    {
                        "textContent": "2 mg, then 2 mg every 2 hours if required.",
                        "html": "<p>2&#8239;mg, then 2&#8239;mg every 2&#8239;hours if required.</p>"
                    },
                    {
                        "textContent": "2.5 mg, then 2.5 mg every 2 hours if required.",
                        "html": "<p>2.5&#8239;mg, then 2.5&#8239;mg every 2&#8239;hours if required.</p>"
                    },
                    {
                        "textContent": "5&#8211;15 mg standard 24 hours.",
                        "html": "<p>5&#8211;15&#8239;mg standard 24&#8239;hours.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "BNF doses for schizophrenia, psychoses, mania, hypomania, and organic brain damage differ from those in product literature.",
                "html": "<p>BNF doses for schizophrenia, psychoses, mania, hypomania, and organic brain damage differ from those in product literature.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "When prescribing, dispensing or administering, check that this injection is the correct preparation&#8212;this preparation is usually used in hospital for the rapid control of an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.",
                "html": "<p>When prescribing, dispensing or administering, check that this injection is the correct preparation&#8212;this preparation is usually used in hospital for the rapid control of an <i>acute episode</i> and should <b>not</b> be confused with depot preparations which are usually used in the community or clinics for <i>maintenance</i> treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Bradycardia",
                "html": "Bradycardia"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "lesions of the basal ganglia",
                "html": "lesions of the basal ganglia"
            },
            {
                "type": "contraindications",
                "textContent": "Parkinson's disease",
                "html": "Parkinson's disease"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "QT-interval prolongation",
                "html": "QT-interval prolongation"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Arteriosclerosis",
                "html": "Arteriosclerosis"
            },
            {
                "type": "cautions",
                "textContent": "hypocalcaemia",
                "html": "hypocalcaemia"
            },
            {
                "type": "cautions",
                "textContent": "hypokalaemia",
                "html": "hypokalaemia"
            },
            {
                "type": "cautions",
                "textContent": "hypomagnesaemia",
                "html": "hypomagnesaemia"
            },
            {
                "type": "cautions",
                "textContent": "metabolic disturbances",
                "html": "metabolic disturbances"
            },
            {
                "type": "cautions",
                "textContent": "subarachnoid haemorrhage",
                "html": "subarachnoid haemorrhage"
            },
            {
                "type": "cautions",
                "textContent": "thyrotoxicosis",
                "html": "thyrotoxicosis"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Avoid concomitant administration of drugs that prolong QT interval.",
                "html": "<p>Avoid concomitant administration of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Depression",
                        "html": "Depression",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dyspnoea",
                        "html": "Dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Bronchospasm",
                        "html": "Bronchospasm",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypoglycaemia",
                        "html": "hypoglycaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "inappropriate antidiuretic hormone secretion",
                        "html": "inappropriate antidiuretic hormone secretion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "photosensitivity reactions",
                        "html": "photosensitivity reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pigmentation",
                        "html": "pigmentation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hypertension",
                        "html": "Hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Less sedating and fewer antimuscarinic or hypotensive symptoms.",
                "html": "<p>Less sedating and fewer antimuscarinic or hypotensive symptoms.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless benefits outweigh risks.\n\nExtrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Avoid unless benefits outweigh risks.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Baseline ECG required before treatment&#8212;assess need for further ECGs during treatment on an individual basis.",
                "html": "<p>Baseline ECG required before treatment&#8212;assess need for further ECGs during treatment on an individual basis.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74919",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74925",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74951",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74933",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_387",
                "label": "Haloperidol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74919",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74925",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74951",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74933",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}